IL10 and B-cell chronic lymphocytic leukemia: Given the potential role of TLRs in CLL pathobiology (30, 31) and well-known regulation of TLR-signaling by IL-10 (25), this observation suggested ruxolitinib might enhance TLR-signaling responses in CLL cells.